Jushi Holdings Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($) $ in Thousands	Total	TGS	Agape	Grover Beach	Nature’s Remedy	Apothecarium	NuLeaf	NuLeaf contingent consideration	Common Stock Super Voting Shares	Common Stock Multiple Voting Shares	Common Stock Subordinate Voting Shares	Common Stock Subordinate Voting Shares TGS	Common Stock Subordinate Voting Shares Agape	Common Stock Subordinate Voting Shares Grover Beach	Common Stock Subordinate Voting Shares Nature’s Remedy	Common Stock Subordinate Voting Shares Apothecarium	Common Stock Subordinate Voting Shares NuLeaf	Common Stock Subordinate Voting Shares NuLeaf contingent consideration	Total Jushi Shareholders' Equity	Total Jushi Shareholders' Equity TGS	Total Jushi Shareholders' Equity Agape	Total Jushi Shareholders' Equity Grover Beach	Total Jushi Shareholders' Equity Nature’s Remedy	Total Jushi Shareholders' Equity Apothecarium	Total Jushi Shareholders' Equity NuLeaf	Total Jushi Shareholders' Equity NuLeaf contingent consideration	Paid-In Capital	Paid-In Capital TGS	Paid-In Capital Agape	Paid-In Capital Grover Beach	Paid-In Capital Nature’s Remedy	Paid-In Capital Apothecarium	Paid-In Capital NuLeaf	Paid-In Capital NuLeaf contingent consideration	Accumulated Deficit	Non-Controlling Interests	Non-Controlling Interests TGS	Non-Controlling Interests Agape
Balance at beginning of period (in shares) at Dec. 31, 2019									149,000	4,000,000	91,592,638
Balance at beginning of period at Dec. 31, 2019	$ 123,034																		$ 113,374								$ 165,436								$ (52,062)	$ 9,660
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares and warrants for cash, net (in shares)											11,500,000
Issuance of shares and warrants for cash, net	29,243																		29,243								29,243
TGS Transaction (in shares)												(4,800,000)
TGS Transaction		$ (2,464)																		$ (7,125)								$ (7,125)									$ 4,661
Purchase of non-controlling interests (in shares)											3,927,911
Purchases of non-controlling interest	(5,625)																		7,395								7,395									(13,020)
Non-controlling interests - Jushi Europe and other transactions	1,994																																			1,994
Shares issued for acquisition (in shares)													769,231
Shares issued for acquisition			$ 2,560																		$ 1,000								$ 1,000							6,221		$ 1,560
Shares issued for restricted stock grants (in shares)											4,548,099
Shares issued upon exercise of warrants (in shares)											24,456,519
Shares issued upon exercise of warrants	55,283																		55,283								55,283
Shares issued upon exercise of stock options (in shares)											26,666
Shares issued upon exercise of stock options	41																		41								41
Share-based compensation (including related parties)	9,592																		9,592								9,592
Warrant expense	175																		175								175
Shares issued for settlements (in shares)											375,000
Shares issued for settlements	1,105																		1,105								1,105
Net income (loss)	(212,515)																		(210,607)																(210,607)	(1,908)
Balance at end of period (in shares) at Dec. 31, 2020									149,000	4,000,000	132,396,064
Balance at end of period at Dec. 31, 2020	2,423																		(524)								262,145								(262,669)	2,947
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Offerings (in shares)											13,685,000
Offerings	85,660																		85,660								85,660
Purchase of non-controlling interests (in shares)											500,000
Purchases of non-controlling interest	0																		1,562								1,562									(1,562)
Shares issued for acquisition (in shares)														49,348	8,700,000
Shares issued for acquisition				$ 368	$ 35,670																	$ 368	$ 35,670							$ 368	$ 35,670
Shares issued upon conversion of debt at maturity (in shares)									(149,000)	(4,000,000)	18,900,000
Shares issued for restricted stock grants (in shares)											65,398
Shares issued upon exercise of warrants (in shares)											8,667,173
Shares issued upon exercise of warrants	$ 24,676																		24,676								24,676
Shares issued upon exercise of stock options (in shares)	291,664										216,133
Shares issued upon exercise of stock options	$ 171																		171								171
Share-based compensation (including related parties)	14,506																		14,506								14,506
Settlement of promissory notes due from related parties (in shares)											(471,757)
Settlement of promissory notes due from related parties	30																		30								30
Net income (loss)	17,479																		20,251																20,251	(2,772)
Balance at end of period (in shares) at Dec. 31, 2021									0	0	182,707,359
Balance at end of period at Dec. 31, 2021	180,983																		182,370								424,788								(242,418)	(1,387)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Offerings (in shares)											3,717,392
Offerings	13,680																		13,680								13,680
Shares issued for acquisition (in shares)																527,704	5,551,264	114,416
Shares issued for acquisition						$ 1,594	$ 15,102	$ 317																$ 1,594	$ 15,102	$ 317						$ 1,594	$ 15,102	$ 317
Shares issued upon conversion of debt at maturity (in shares)											910,000
Shares issued upon conversion of debt at maturity	2,412																		2,412								2,412
Shares issued upon exercise of warrants (in shares)											3,176,601
Shares issued upon exercise of warrants	$ 10,578																		10,578								10,578
Shares issued upon exercise of stock options (in shares)	324,998										121,976
Shares issued upon exercise of stock options	$ 26																		26								26
Share-based compensation (including related parties)	23,073																		23,073								23,073
Shares canceled upon forfeiture of non-vested restricted stock (in shares)											(140,340)
Collection of note receivable from employee shareholder	450																		450								450
Net income (loss)	(202,324)																		(202,324)																(202,324)
Balance at end of period (in shares) at Dec. 31, 2022									0	0	196,686,372
Balance at end of period at Dec. 31, 2022	$ 45,891																		$ 47,278								$ 492,020								$ (444,742)	$ (1,387)